Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia

Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia Repeated therapy of hairy cell leukaemia (HCL) with treatments that have potential long‐term toxicities has raised concerns regarding increased risk for younger patients. We compared clinical outcomes and disease complications in 63 patients with HCL aged ≤40 years at diagnosis with 268 patients >40 years treated at Memorial Sloan Kettering Cancer Center. The rate of complete remission following initial therapy was 87% and 83% (P = 0·71) and estimated 10‐year overall survival was 100% and 82% (P = 0·25) in younger and older patients, respectively. Younger patients required therapy earlier and had a significantly shorter time between first and second therapy (median: 63 months vs. 145 months) (P = 0·008). Younger patients required significantly more lines of therapy during follow‐up. The 10‐year cumulative incidence of secondary malignancies in young and old patients was 0·205 and 0·287, respectively (P = 0·22). The incidence of secondary cancers in patients aged >40 years at diagnosis increased with the number of treatments for HCL (P = 0·018). These results highlight that young patients with HCL have shorter responses to treatment and require more lines of therapy to maintain disease control, while attaining similar long‐term survival. This has implications in the design of future clinical trials given our findings that secondary malignancies increase with more chemotherapy exposure. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Haematology Wiley

Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia

Loading next page...
 
/lp/wiley/treatment-outcomes-and-secondary-cancer-incidence-in-young-patients-KC78Z0vCBd

References (14)

Publisher
Wiley
Copyright
Copyright © 2016 John Wiley & Sons Ltd
ISSN
0007-1048
eISSN
1365-2141
DOI
10.1111/bjh.14207
pmid
27351754
Publisher site
See Article on Publisher Site

Abstract

Repeated therapy of hairy cell leukaemia (HCL) with treatments that have potential long‐term toxicities has raised concerns regarding increased risk for younger patients. We compared clinical outcomes and disease complications in 63 patients with HCL aged ≤40 years at diagnosis with 268 patients >40 years treated at Memorial Sloan Kettering Cancer Center. The rate of complete remission following initial therapy was 87% and 83% (P = 0·71) and estimated 10‐year overall survival was 100% and 82% (P = 0·25) in younger and older patients, respectively. Younger patients required therapy earlier and had a significantly shorter time between first and second therapy (median: 63 months vs. 145 months) (P = 0·008). Younger patients required significantly more lines of therapy during follow‐up. The 10‐year cumulative incidence of secondary malignancies in young and old patients was 0·205 and 0·287, respectively (P = 0·22). The incidence of secondary cancers in patients aged >40 years at diagnosis increased with the number of treatments for HCL (P = 0·018). These results highlight that young patients with HCL have shorter responses to treatment and require more lines of therapy to maintain disease control, while attaining similar long‐term survival. This has implications in the design of future clinical trials given our findings that secondary malignancies increase with more chemotherapy exposure.

Journal

British Journal of HaematologyWiley

Published: Nov 1, 2016

Keywords: ; ; ; ;

There are no references for this article.